Thyroid cancer

Lancet. 2016 Dec 3;388(10061):2783-2795. doi: 10.1016/S0140-6736(16)30172-6. Epub 2016 May 27.

Abstract

Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer-medullary and anaplastic-are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.

Trial registration: ClinicalTrials.gov NCT02657369 NCT02244463 NCT01240590 NCT02152137 NCT02239900.

Publication types

  • Review

MeSH terms

  • Carcinoma, Neuroendocrine / diagnosis*
  • Carcinoma, Neuroendocrine / diagnostic imaging
  • Carcinoma, Neuroendocrine / surgery*
  • Diagnosis, Differential
  • Disease-Free Survival*
  • Humans
  • Severity of Illness Index
  • Thyroid Neoplasms / diagnosis*
  • Thyroid Neoplasms / diagnostic imaging
  • Thyroid Neoplasms / genetics
  • Thyroid Neoplasms / physiopathology
  • Thyroid Neoplasms / surgery*

Supplementary concepts

  • Thyroid cancer, medullary

Associated data

  • ClinicalTrials.gov/NCT02657369
  • ClinicalTrials.gov/NCT02244463
  • ClinicalTrials.gov/NCT01240590
  • ClinicalTrials.gov/NCT02152137
  • ClinicalTrials.gov/NCT02239900